CD226 and neoplasm: CAR-NKs potentially eliminate tumor cells via NCRs, NKG2D, DNAM-1 (CD226) and certain activating KIRs (KIR2DS1, KIR2DS4, and KIR2DL4) independent of CAR, as well as through CD16-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) [51].